Physician profile
Sana Bloch
NPI 1760456933
$5,200.42
in general payments reported to CMS, 2019-2025
30 companies · $50.46 in 2025
The $50.46 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,255 · 2020: $606 · 2021: $965 · 2022: $681 · 2023: $618 · 2024: $23.61 · 2025: $50.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $753.15 | 2019-2023 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $536.23 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $530.53 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $377.16 | 2019-2023 | Austedo |
| Sunovion Pharmaceuticals INC. | $323.47 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $272.20 | 2019-2023 | |
| Abbvie INC. | $264.95 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Biogen, INC. | $216.40 | 2019-2021 | |
| Genzyme Corporation | $187.63 | 2019-2022 | |
| Allergan, INC. | $181.95 | 2019-2021 | |
| Abbott Laboratories | $159.76 | 2021-2022 | |
| Ucb, INC. | $155.91 | 2019-2021 | |
| Kyowa Kirin, INC. | $151.36 | 2020-2021 | |
| Acorda Therapeutics, INC | $141.59 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $124.83 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $106.56 | 2021-2023 | Uplizna |
| Argenx US, INC. | $104.60 | 2023 | Vyvgart |
| Lilly USA, LLC | $101.29 | 2019-2020 | |
| Sk Life Science, INC. | $91.34 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $85.70 | 2019-2020 | |
| Amgen INC. | $72.42 | 2019-2025 | Uplizna |
| Janssen Pharmaceuticals, INC | $58.41 | 2021 | |
| Amneal Pharmaceuticals LLC | $40.90 | 2019-2022 | |
| Pfizer INC. | $37.35 | 2023 | |
| Vertical Pharmaceuticals, LLC | $29.74 | 2019 | |
| Mdd US Operations, LLC | $27.60 | 2022 | |
| Celgene Corporation | $19.85 | 2023 | |
| Neurocrine Biosciences, INC. | $18.19 | 2021 | |
| Sumitomo Pharma America, INC. | $15.22 | 2023 | Aptiom |
| Eisai INC. | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sana Bloch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.